RESVERLOGIX CORP.
CALGARY, ALBERTA, A0 · CIK 0001372821 · Biotech · Public
Apabetalone, a small-molecule BET protein inhibitor therapeutic
resverlogix.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $12M
- 2 Form D · Dec 2011
- 178 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 26
- 10 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020112012
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,486,899 | |
| Private capital raised | Form D · SEC | $1,841,995 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2885 | JANUSQ, LLC | — | — |
| 2886 | FEMTOFLUIDICS INCORPORATED | — | — |
| 2887 | Origin Holdings Inc. | — | $137M |
| 2888 | RESVERLOGIX CORP. | — | $12M |
| 2889 | Cullinan Therapeutics | — | — |
| 2890 | Network Music Partners, LLC | — | $205K |
| 2891 | Sage Therapeutics | — | $698M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- A. CannExecutive Officer
- F. GordonExecutive Officer
- Arthur HigginsDirector
- Peter JohannDirector
- Jan JohanssonExecutive Officer
- Kenneth LebiodaExecutive Officer
- Donald McCaffreyDirector · Executive Officer
- Kelly McNeillDirector
- Tina RarickExecutive Officer
- Eldon SmithDirector
- Gregory WagnerExecutive Officer
- Norman WongExecutive Officer
- Peter YoungExecutive Officer
- Kenneth ZuerblisDirector
Patents
- Methods For Improving Renal Function With A Combination Of A Bet Bromodomain Inhibitor And A Sodium Dependent Glucose Transport 2 Inhibitorgranted
- Methods Of Treatment And/or Prevention Of Major Adverse Cardiovascular Events (mace) With A Combination Of A Bet Bromodomain Inhibitor And A Sodium Dependent Glucose Transport 2 Inhibitorgranted
- Methods For Lowering HBA1C Level With A Combination Of A Bet Bromodomain Inhibitor And A Sodium Dependent Glucose Transport 2 Inhibitorapplication
- Methods Of Treatment And/or Prevention Of Major Adverse Cardiovascular Events (mace) With A Combination Of A Bet Bromodomain Inhibitor And A Dipeptidyl Peptidase 4 Inhibitorapplication
- Anti-inflammatory Agentsgranted
- Compounds For The Prevention And Treatment Of Cardiovascular Diseasesapplication
- Novel Anti-inflammatory Agentsgranted
- Compounds For The Prevention And Treatment Of Cardiovascular Diseasesapplication
- Compositions And Therapeutic Methods For The Treatment Of Complement-associated Diseasesgranted
- Novel Anti-inflammatory Agentsapplication
- Compounds For The Prevention And Treatment Of Cardiovascular Diseasesgranted
- Novel Anti-inflammatory Agentsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.